CL2007003422A1 - Uso de un antagonista de la proteina pik3r3 para inhibir el crecimiento de un glioma que expresa dicha proteina; y metodo para diagnosticar la presencia de un glioma en un mamifero. - Google Patents

Uso de un antagonista de la proteina pik3r3 para inhibir el crecimiento de un glioma que expresa dicha proteina; y metodo para diagnosticar la presencia de un glioma en un mamifero.

Info

Publication number
CL2007003422A1
CL2007003422A1 CL200703422A CL2007003422A CL2007003422A1 CL 2007003422 A1 CL2007003422 A1 CL 2007003422A1 CL 200703422 A CL200703422 A CL 200703422A CL 2007003422 A CL2007003422 A CL 2007003422A CL 2007003422 A1 CL2007003422 A1 CL 2007003422A1
Authority
CL
Chile
Prior art keywords
protein
gliom
antigonist
mammer
pik3r3
Prior art date
Application number
CL200703422A
Other languages
English (en)
Inventor
Heidi Soroceanu Lilia Phillips
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2007003422A1 publication Critical patent/CL2007003422A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CL200703422A 2006-11-29 2007-11-28 Uso de un antagonista de la proteina pik3r3 para inhibir el crecimiento de un glioma que expresa dicha proteina; y metodo para diagnosticar la presencia de un glioma en un mamifero. CL2007003422A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86776106P 2006-11-29 2006-11-29

Publications (1)

Publication Number Publication Date
CL2007003422A1 true CL2007003422A1 (es) 2008-06-20

Family

ID=39468664

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703422A CL2007003422A1 (es) 2006-11-29 2007-11-28 Uso de un antagonista de la proteina pik3r3 para inhibir el crecimiento de un glioma que expresa dicha proteina; y metodo para diagnosticar la presencia de un glioma en un mamifero.

Country Status (11)

Country Link
US (2) US20080221014A1 (es)
EP (1) EP2091565A2 (es)
JP (1) JP2010511060A (es)
AR (1) AR064008A1 (es)
AU (1) AU2007325259A1 (es)
CA (1) CA2669184A1 (es)
CL (1) CL2007003422A1 (es)
IL (1) IL198425A0 (es)
MX (1) MX2009005400A (es)
TW (1) TW200831536A (es)
WO (1) WO2008067351A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103269710B (zh) * 2010-09-23 2015-08-19 科学与工业研究会 用于预测gbm患者的存活的替莫唑胺对top2a的抑制
CN102321158B (zh) * 2011-08-23 2013-03-27 常州德健生物科技有限公司 阻止细胞dna合成抑制细胞增殖的多肽及用途
JP2015501138A (ja) 2011-10-07 2015-01-15 ユニヴェルシテ モンペリエ ドゥ シアンス エ テクニックＵｎｉｖｅｒｓｉｔｅ Ｍｏｎｔｐｅｌｌｉｅｒ ２ Ｓｃｉｅｎｃｅｓ Ｅｔ Ｔｅｃｈｎｉｑｕｅｓ 神経膠腫の予後予測
TWI692777B (zh) * 2018-11-16 2020-05-01 長庚醫療財團法人高雄長庚紀念醫院 智能化急性腎損傷藥物警示系統
CN111778334A (zh) * 2020-07-13 2020-10-16 中山大学孙逸仙纪念医院 一种CircRNA作为肝癌肿瘤标志物的评价方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165170A (en) * 1998-01-29 2000-12-26 International Business Machines Corporation Laser dermablator and dermablation
MXPA04006980A (es) * 2002-01-18 2004-11-10 Pf Medicament Anticuerpos novedosos anti-receptor del factor de crecimiento i tipo insulina, y usos de los mismos.
EP1628679A2 (en) * 2003-05-23 2006-03-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumors of glial origin
MXPA05013210A (es) * 2003-06-05 2006-03-09 Warner Lambert Co Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos.
US7449477B2 (en) * 2003-11-25 2008-11-11 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
CA2598409A1 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
US20080014598A1 (en) * 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Phospho-specific antibodies to pi3k regulatory subunit and uses thereof

Also Published As

Publication number Publication date
JP2010511060A (ja) 2010-04-08
US20090269351A1 (en) 2009-10-29
IL198425A0 (en) 2010-02-17
TW200831536A (en) 2008-08-01
EP2091565A2 (en) 2009-08-26
MX2009005400A (es) 2009-06-05
WO2008067351A2 (en) 2008-06-05
US20080221014A1 (en) 2008-09-11
AU2007325259A1 (en) 2008-06-05
AU2007325259A2 (en) 2009-07-02
WO2008067351A3 (en) 2008-11-06
AR064008A1 (es) 2009-03-04
CA2669184A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
ES2575152T3 (es) Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
NI200900081U (es) Anticuerpos agonistas de trkb y sus usos.
BRPI0922885A2 (pt) anticorpos humanos de alta afinidade para a pcsk9.
HN2008001720A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
BRPI0914319A2 (pt) anticorpos estáveis e solúveis que inibem tnfalfa
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
CU23871B1 (es) Composiciones y métodos de uso para anticuerpos de dickkopf-1
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
CL2007003791A1 (es) Compuestos derivados de piperidina, inhibidores de la proteina quinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para inhibir el crecimiento celular anormal.
BRPI0813306A2 (pt) composto, composição farmacêutica, método para produzir a inibição de uma cisteína protease em um mamífero, e, uso de um composto.
BRPI0918141A2 (pt) conjunto de embalagem para marinada sob demanda e método para fornecer o mesmo
DK1981853T3 (da) Substituerede imidazoler samt anvendelse deraf som pesticider
BRPI0716327A2 (pt) Composto de fenilpropionamida e uso
CL2013000098A1 (es) Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso.
CL2007002837A1 (es) Uso de fenitoina para tratar mucositis oral.
NO20081618L (no) Anvendelse av proteiner som en antiskumdannende komponent i drivstoff
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas
BRPI0909885A2 (pt) composição decorativa e método para sua utilização
BR112012013247A2 (pt) conjunto submarino e método para uso em operações submarinas"
BRPI0717496A2 (pt) Polímeros ramificados e métodos para sua síntese e uso
DK1828649T3 (da) Tryksatte fluidcylindre
CL2007003422A1 (es) Uso de un antagonista de la proteina pik3r3 para inhibir el crecimiento de un glioma que expresa dicha proteina; y metodo para diagnosticar la presencia de un glioma en un mamifero.
CL2013001565A1 (es) Metodo para tratar la ingesta excesiva o comer compulsivamente, que comprende el uso de bupropion y naltrexona y la composicion farmaceutica que comprende a ambos compuestos.
BRPI0807989A2 (pt) Composto de éster e uso do mesmo.